MedDataX Logo

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

NCT ID: NCT00370721

Last Updated: 2008-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Proliferative diabetic retinopathy(PDR) Pan retinal photocoagulation (PRP) Vitreous hemorrhage Traction retinal detachment Neovascularization on disc (NVD) Neovascularization elsewhere (NVE) Fibrous proliferation on disc (FPD) Fibrous proliferaiton elsewhere (FPE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

Group Type EXPERIMENTAL

bevacizumab

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cases of active progressive PDR with history of scatter laser photocoagulation

Exclusion Criteria

* history of vitrectomy
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamid Ahmadieh, MD

Role: PRINCIPAL_INVESTIGATOR

Ophthalmic Research Center of Shaheed Beheshti Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamid Ahmadieh, MD

Tehran, Tehran Province, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hamid Ahmadieh, MD

Role: CONTACT

Phone: +98 21 22585952

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hamid Ahmadieh, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8538

Identifier Type: -

Identifier Source: org_study_id